Moderna and merck announce mrna-4157/v940, an investigational personalized mrna cancer vaccine, in combination with keytruda(r) (pembrolizumab), was granted breakthrough therapy designation by the fda for adjuvant treatment of patients with high-risk mela

Designation based on positive data from phase 2b keynote-942/mrna-4157-p201 trial cambridge, ma and rahway, nj / accesswire / february 22, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced that mrna-4157/v940, an investigational personalized mrna cancer vaccine, in combination with keytruda, merck's anti-pd-1 therapy, has been granted breakthrough therapy designation by the u.s. food and drug administration (fda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. the fda granted breakthrough therapy designation based on positive data from the phase 2b keynote-942/mrna-4157-p201 trial.
MRNA Ratings Summary
MRNA Quant Ranking